300158 振东制药
已收盘 01-12 15:00:00
资讯
新帖
简况
每周股票复盘:振东制药(300158)聘任王锐为新任总裁
证券之星 · 01-03
每周股票复盘:振东制药(300158)聘任王锐为新任总裁
振东制药(300158)披露副总裁、董事会秘书辞职暨聘任总裁公告,12月31日股价上涨0.35%
证券之星 · 2025-12-31
振东制药(300158)披露副总裁、董事会秘书辞职暨聘任总裁公告,12月31日股价上涨0.35%
振东制药副总裁、董事会秘书王哲宇辞职,聘任王锐为总裁
北京商报 · 2025-12-31
振东制药副总裁、董事会秘书王哲宇辞职,聘任王锐为总裁
振东制药(300158.SZ)拟3000万元参与设立基金投资于生物医药领域
智通财经 · 2025-12-26
振东制药(300158.SZ)拟3000万元参与设立基金投资于生物医药领域
振东制药(300158)披露关于股东股份解押及质押的公告,12月19日股价上涨0.83%
证券之星 · 2025-12-19
振东制药(300158)披露关于股东股份解押及质押的公告,12月19日股价上涨0.83%
振东制药(300158)披露第四期员工持股计划,12月18日股价下跌0.49%
证券之星 · 2025-12-18
振东制药(300158)披露第四期员工持股计划,12月18日股价下跌0.49%
振东制药:达霏欣等产品通过阿里健康大药房销售
证券之星 · 2025-12-18
振东制药:达霏欣等产品通过阿里健康大药房销售
振东制药拟推2.5亿元第四期员工持股计划,核心骨干自愿参与
中金财经 · 2025-12-15
振东制药拟推2.5亿元第四期员工持股计划,核心骨干自愿参与
振东制药(300158)披露参股公司核心产品新药申请获国家药监局受理,12月10日股价上涨0.31%
证券之星 · 2025-12-10
振东制药(300158)披露参股公司核心产品新药申请获国家药监局受理,12月10日股价上涨0.31%
振东制药:乳杆菌二联活菌胶囊新药申请获受理
证券之星 · 2025-12-10
振东制药:乳杆菌二联活菌胶囊新药申请获受理
振东制药(300158.SZ):阴道用乳杆菌二联活菌胶囊的新药申请获受理
智通财经 · 2025-12-10
振东制药(300158.SZ):阴道用乳杆菌二联活菌胶囊的新药申请获受理
振东制药(300158)披露增加股东大会临时提案,12月03日股价下跌2.09%
中金财经 · 2025-12-03
振东制药(300158)披露增加股东大会临时提案,12月03日股价下跌2.09%
振东制药董事会薪酬与考核委员会实施细则获通过,强化治理与激励
中金财经 · 2025-12-03
振东制药董事会薪酬与考核委员会实施细则获通过,强化治理与激励
振东制药:子公司为欧加隆提供米诺地尔搽剂制造服务
证券之星 · 2025-12-02
振东制药:子公司为欧加隆提供米诺地尔搽剂制造服务
振东制药拟变更公司章程 取消监事会并调整治理结构
中金财经 · 2025-12-02
振东制药拟变更公司章程 取消监事会并调整治理结构
振东制药(300158)股东山西振东健康产业集团有限公司质押1560万股,占总股本1.57%
证券之星 · 2025-11-26
振东制药(300158)股东山西振东健康产业集团有限公司质押1560万股,占总股本1.57%
振东制药:中药材海外出口业务稳步推进
证券之星 · 2025-11-25
振东制药:中药材海外出口业务稳步推进
振东制药(300158)披露关于回购股份注销完成暨股份变动的公告,11月24日股价上涨2.24%
证券之星 · 2025-11-24
振东制药(300158)披露关于回购股份注销完成暨股份变动的公告,11月24日股价上涨2.24%
振东制药:公司无禽流感用药
证券之星 · 2025-11-20
振东制药:公司无禽流感用药
股市必读:振东制药(300158)11月14日董秘有最新回复
证券之星 · 2025-11-17
股市必读:振东制药(300158)11月14日董秘有最新回复
加载更多
公司概况
公司名称:
山西振东制药股份有限公司
所属行业:
医药制造业
上市日期:
2011-01-07
主营业务:
山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。公司荣获“全国先进基层党组织”“全国脱贫攻坚先进集体”两个荣誉称号,荣获“第七届百姓安全用药”放心药奖、“山西省著名商标”等荣誉。
发行价格:
38.80
{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":6.27,"timestamp":1768201398000,"preClose":6.27,"halted":0,"volume":39252512,"delay":0,"changeRate":0,"floatShares":992000000,"shares":992000000,"eps":-1.3588,"marketStatus":"已收盘","change":0,"latestTime":"01-12 15:00:00","open":6.28,"high":6.32,"low":6.21,"amount":245000000,"amplitude":0.0175,"askPrice":6.27,"askSize":1574,"bidPrice":6.26,"bidSize":3182,"shortable":0,"etf":0,"ttmEps":-1.3588,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"adjPreClose":6.27,"symbolType":"stock","openAndCloseTimeList":[[1768181400000,1768188600000],[1768194000000,1768201200000]],"highLimit":6.9,"lowLimit":5.64,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":992303056,"isCdr":false,"pbRate":1.7,"roa":"--","roe":"0.56%","epsLYR":-1.2977,"committee":0.085602,"marketValue":6222000000,"turnoverRate":0.0396,"status":2,"floatMarketCap":6218000000},"requestUrl":"/m/hq/s/300158","defaultTab":"news","newsList":[{"id":"2600067874","title":"每周股票复盘:振东制药(300158)聘任王锐为新任总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067874","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067874?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:33","pubTimestamp":1767378791,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,振东制药报收于5.81元,较上周的5.94元下跌2.19%。本周,振东制药12月29日盘中最高价报5.96元。振东制药当前最新总市值57.65亿元,在中药板块市值排名39/67,在两市A股市值排名3013/5181。本周关注点公司公告汇总:振东制药聘任王锐先生为公司总裁,任期至第六届董事会届满。表决结果为9票同意、0票反对、0票弃权,会议由董事长李昆主持。王锐先生现任公司营销总裁,未持有公司股份,与控股股东无关联关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","BK0239","300158"],"gpt_icon":0},{"id":"2595228772","title":"振东制药(300158)披露副总裁、董事会秘书辞职暨聘任总裁公告,12月31日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595228772","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595228772?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:12","pubTimestamp":1767190341,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,振东制药报收于5.81元,较前一交易日上涨0.35%,最新总市值为57.65亿元。公司近日发布公告称,山西振东制药股份有限公司董事会收到副总裁、董事会秘书王哲宇先生的书面辞职报告,其因工作岗位调动申请辞去职务,辞职后仍在公司担任其他职务。董事长李昆先生将代行董事会秘书职责,直至新任秘书聘任到位。同时,公司第六届董事会第十一次会议审议通过聘任王锐先生为公司总裁,任期至第六届董事会届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"gpt_icon":0},{"id":"2595775323","title":"振东制药副总裁、董事会秘书王哲宇辞职,聘任王锐为总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2595775323","media":"北京商报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595775323?lang=zh_cn&edition=full","pubTime":"2025-12-31 18:38","pubTimestamp":1767177480,"startTime":"0","endTime":"0","summary":"北京商报讯12月31日,振东制药发布公告称,王哲宇因工作岗位调动申请辞去公司副总裁、董事会秘书职务,辞职后在公司担任其他职务。在公司正式聘任董事会秘书之前,由董事长李昆代为履行董事会秘书职责。 同时,公司召开董事会会议,同意聘任王锐为总裁,任期自本次董事会审议通过之日起至公司第六届董事会任期届满之日止。(文章来源:北京商报)\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-31/doc-inhesxnk3641271.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-31/doc-inhesxnk3641271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300158","BK0239","BK0060","BK0186"],"gpt_icon":0},{"id":"2594329885","title":"振东制药(300158.SZ)拟3000万元参与设立基金投资于生物医药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2594329885","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594329885?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:47","pubTimestamp":1766742434,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)发布公告,为满足战略发展需求,充分借助专业投资机构的力量及资源优势,整合多方资源以获取长期投资回报、提升综合竞争力,在不影响公司日常经营和发展、有效控制投资风险的前提下,公司近日与海南隆门私募基金管理合伙企业(有限合伙)、温诺谣、北京新医咨询有限公司、上海维诺润诚医药科技有限公司共同签署了《温州隆门汇鑫三号创业投资合伙企业(有限合伙)合伙协议》。根据合伙协议约定,公司作为有限合伙人以自有资金认缴出资3000万元人民币,出资比例为28.5687%,以认缴出资额为限承担有限责任,主要投资于生物医药领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","BK0239","300158","BK0186","399441","161726"],"gpt_icon":0},{"id":"2592696198","title":"振东制药(300158)披露关于股东股份解押及质押的公告,12月19日股价上涨0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592696198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592696198?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:25","pubTimestamp":1766154317,"startTime":"0","endTime":"0","summary":"截至2025年12月19日收盘,振东制药报收于6.09元,较前一交易日上涨0.83%,最新总市值为60.43亿元。公司近日发布公告称,山西振东制药股份有限公司控股股东振东集团近日办理了部分股份解押及质押手续。本次解押股份合计40,600,000股,占公司总股本4.09%;同时质押14,500,000股,占公司总股本1.46%,质权人均为中国银行股份有限公司长治市分行,质押用途为自身生产经营。本次变动后,振东集团累计质押股份占其所持股份比例为44.56%,占公司总股本13.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900039358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2592690420","title":"振东制药(300158)披露第四期员工持股计划,12月18日股价下跌0.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592690420","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592690420?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:23","pubTimestamp":1766067830,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘,振东制药报收于6.04元,较前一交易日下跌0.49%,最新总市值为59.94亿元。该股当日开盘6.06元,最高6.13元,最低6.02元,成交额达8232.16万元,换手率为1.37%。此外,会议还通过了关于变更注册资本暨修订《公司章程》的议案,以及修订《股东会议事规则》等9项相关制度的议案。其中,变更注册资本暨修订公司章程的议案作为特别决议事项,已获得出席股东大会股东所持表决权的三分之二以上通过。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800038742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300158","BK0186"],"gpt_icon":0},{"id":"2592905206","title":"振东制药:达霏欣等产品通过阿里健康大药房销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2592905206","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592905206?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:51","pubTimestamp":1766062280,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)12月17日在投资者关系平台上答复投资者关心的问题。投资者提问:公司与阿里健康是否有线上渠道合作?振东制药回复:尊敬的投资者您好!公司的达霏欣牌米诺地尔擦剂、脾肾两助丸等产品通过阿里健康大药房销售。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800035342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK1589","300158","BK1247","00241","BK0239","BK1571","BK1502","BK1189","BK1142","BK0186","BK1515","BK1501","BK1584","BK1591","BK1610","BK1615","BK1617"],"gpt_icon":0},{"id":"2591461183","title":"振东制药拟推2.5亿元第四期员工持股计划,核心骨干自愿参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2591461183","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591461183?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:39","pubTimestamp":1765787952,"startTime":"0","endTime":"0","summary":"中访网数据 山西振东制药股份有限公司于2025年11月19日召开第六届董事会第八次会议,审议通过了《第四期员工持股计划(草案)》及相关议案。该计划拟筹集资金总额上限为2.5亿元,股票来源为通过二级市场购买等方式获得。计划存续期不超过36个月,由公司自行管理。公司已召开职工代表大会征求意见,董事会薪酬与考核委员会出具了审核意见。该员工持股计划尚需提交公司2025年第二次临时股东大会审议批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251215/31865999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300158","BK0186","BK0060","BK0239"],"gpt_icon":0},{"id":"2590538904","title":"振东制药(300158)披露参股公司核心产品新药申请获国家药监局受理,12月10日股价上涨0.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538904","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538904?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:12","pubTimestamp":1765375925,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘,振东制药报收于6.38元,较前一交易日上涨0.31%,最新总市值为63.31亿元。该股当日开盘6.42元,最高6.46元,最低6.28元,成交额达1.14亿元,换手率为1.82%。近日,振东制药发布关于广东龙创基药业有限公司核心产品阴道用乳杆菌二联活菌胶囊的新药申请获国家药品监督管理局受理的公告。振东制药目前持有龙创基药业6.015%股权,后续有权受让更多股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300158","BK0186"],"gpt_icon":0},{"id":"2590582794","title":"振东制药:乳杆菌二联活菌胶囊新药申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590582794","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590582794?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:52","pubTimestamp":1765371171,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药12月10日在投资者关系平台上答复投资者关心的问题。公司参股的龙创基药业核心产品乳杆菌二联活菌胶囊提交的新药申请于近日获得受理。根据国家医保目录纳入原则,药品需先在国内获批上市后方具备申报资格。前述传闻不属实,公司目前不存在应披露而未披露的重大重组事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000037993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300158","BK0186"],"gpt_icon":0},{"id":"2590301190","title":"振东制药(300158.SZ):阴道用乳杆菌二联活菌胶囊的新药申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590301190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590301190?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:52","pubTimestamp":1765353124,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)公告,公司参股的广东龙创基药业有限公司(简称“龙创基药业”)核心产品“阴道用乳杆菌二联活菌胶囊”的新药申请(NDA)已获中国国家药品监督管理局药品审评中心(CDE)受理。该药品为复方制剂,主要成分为格氏乳杆菌和鼠李糖乳杆菌活菌,用于阴道菌群恢复,细菌性阴道病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"振东制药(300158.SZ):阴道用乳杆菌二联活菌胶囊的新药申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0186","BK0060","300158","BK0239"],"gpt_icon":0},{"id":"2588014447","title":"振东制药(300158)披露增加股东大会临时提案,12月03日股价下跌2.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588014447","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588014447?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:20","pubTimestamp":1764753640,"startTime":"0","endTime":"0","summary":"公司近日发布公告称,董事会决定于2025年12月18日召开2025年第二次临时股东大会,会议将审议包括第四期员工持股计划相关议案、变更注册资本暨修订公司章程、修订股东会议事规则等9项制度的议案。新增临时提案由控股股东山西振东健康产业集团有限公司于2025年12月2日提出,董事会同意将其提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251203/31841798.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0186","BK0060","300158","BK0239"],"gpt_icon":0},{"id":"2588067521","title":"振东制药董事会薪酬与考核委员会实施细则获通过,强化治理与激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2588067521","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588067521?lang=zh_cn&edition=full","pubTime":"2025-12-03 08:00","pubTimestamp":1764720020,"startTime":"0","endTime":"0","summary":"中访网数据 山西振东制药股份有限公司董事会近日审议通过了《董事会薪酬与考核委员会实施细则》,旨在进一步完善公司治理结构,建立健全对董事及高级管理人员的薪酬与考核管理制度。根据细则,薪酬与考核委员会由三名董事组成,其中独立董事需占两名,主要负责制定并审查公司董事及高级管理人员的薪酬政策与方案,制定考核标准并进行绩效评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251203/31840061.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2588905355","title":"振东制药:子公司为欧加隆提供米诺地尔搽剂制造服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2588905355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588905355?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:53","pubTimestamp":1764679981,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药12月02日在投资者关系平台上答复投资者关心的问题。持有人是振东安欣!这品牌是美企业上市公司欧加隆公司的,旗下还有:内舒拿,妈富隆等等知名品牌,公司也是默沙东分拆独立出来的医疗健康公司!请问公司是否有与欧加隆合作?是否有开拓海外市场做准备?米诺地尔FDA认证是否批复?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200036954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","300158","BK0060","BK0239"],"gpt_icon":0},{"id":"2588058101","title":"振东制药拟变更公司章程 取消监事会并调整治理结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058101","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588058101?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:30","pubTimestamp":1764678652,"startTime":"0","endTime":"0","summary":"中访网数据 山西振东制药股份有限公司于12月2日召开董事会及监事会会议,审议通过了关于变更注册资本及修订《公司章程》等一系列议案。更为关键的是,公司计划根据新《公司法》调整治理架构,拟不再设置监事会,其相关职权将由董事会下设的审计委员会行使。修订后的《公司章程》将删除所有涉及“监事”、“监事会”的条款及第七章“监事会”的全部内容,相关监事将自动解任。该议案尚需提交公司股东大会审议批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251202/31839380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0060","BK0186","300158","BK0239"],"gpt_icon":0},{"id":"2586255178","title":"振东制药(300158)股东山西振东健康产业集团有限公司质押1560万股,占总股本1.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586255178","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586255178?lang=zh_cn&edition=full","pubTime":"2025-11-26 18:40","pubTimestamp":1764153625,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药11月26日公开信息显示,股东山西振东健康产业集团有限公司向中国银行股份有限公司长治市分行合计质押1560.0万股,占总股本1.57%。质押详情见下表:截止本公告日,股东山西振东健康产业集团有限公司已累计质押股份1.61亿股,占其持股总数的53.19%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600029034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0186","BK0239"],"gpt_icon":0},{"id":"2586473392","title":"振东制药:中药材海外出口业务稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586473392?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:51","pubTimestamp":1764075076,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,请问贵司中药材海外出口业务近况如何?对未来有何计划?振东制药回复:尊敬的投资者您好!公司的相关业务正稳步推进。公司当前的中药材海外出口业务以山西道地中药材和基地大宗药材为基础,并正逐步加大中药材的出口销售比例。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036201.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0060","300158","BK0239"],"gpt_icon":0},{"id":"2585607914","title":"振东制药(300158)披露关于回购股份注销完成暨股份变动的公告,11月24日股价上涨2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585607914","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585607914?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:17","pubTimestamp":1763993826,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘,振东制药报收于6.4元,较前一交易日上涨2.24%,最新总市值为63.51亿元。该股当日开盘6.26元,最高6.45元,最低6.25元,成交额达1.56亿元,换手率为2.48%。公司于近日发布公告称,山西振东制药股份有限公司于2025年11月21日完成回购股份注销手续,共计注销13,016,700股,占注销前总股本的1.29%。公司总股本由1,005,319,756股减少至992,303,056股。本次注销不影响公司财务状况和经营成果,股份分布仍符合上市条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0186","BK0060"],"gpt_icon":0},{"id":"2584312051","title":"振东制药:公司无禽流感用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2584312051","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584312051?lang=zh_cn&edition=full","pubTime":"2025-11-20 20:52","pubTimestamp":1763643132,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)11月19日在投资者关系平台上答复投资者关心的问题。投资者提问:有没有禽流感用的药振东制药回复:尊敬的投资者您好!公司主营业务为肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司无禽流感用药。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000035616.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","BK0239","300158"],"gpt_icon":0},{"id":"2584969868","title":"股市必读:振东制药(300158)11月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2584969868","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584969868?lang=zh_cn&edition=full","pubTime":"2025-11-17 01:52","pubTimestamp":1763315534,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘,振东制药报收于7.37元,上涨3.08%,换手率7.92%,成交量79.54万手,成交额5.87亿元。董秘最新回复投资者: 你好,董秘,同为创新药,贵公司和常山药业差距在哪儿?回购固然是好,但依然建议公司高层把资金用来收购好的标的企业,实现新的增长谢谢董秘: 答:尊敬的投资者您好!当日关注点来自交易信息汇总:11月14日主力资金净流出1760.73万元,显示主力资金持续离场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700000689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0060","BK0186"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768206838258,"stockEarnings":[{"period":"1week","weight":0.0792},{"period":"1month","weight":-0.0172},{"period":"3month","weight":-0.0833},{"period":"6month","weight":0.334},{"period":"1year","weight":0.3397},{"period":"ytd","weight":0.0792}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"48391人(较上一季度增加4.89%)","perCapita":"20493股","listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","registeredCapital":"99230万元","survey":" 山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。公司荣获“全国先进基层党组织”“全国脱贫攻坚先进集体”两个荣誉称号,荣获“第七届百姓安全用药”放心药奖、“山西省著名商标”等荣誉。","listedPrice":38.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}